Novastan (Argatroban Monohydrate)

Novastan (argatroban) is used for anticoagulation in clinical situations where thrombin inhibition is required.

• Heparin‑induced thrombocytopenia (HIT): provides alternative anticoagulation to prevent clot formation in patients who cannot receive heparin.
• Percutaneous coronary intervention (PCI): maintains procedural anticoagulation to reduce risk of thrombotic complications during coronary angioplasty.
• Acute coronary syndromes (ACS): helps prevent and treat thrombotic events associated with unstable angina or myocardial infarction.

• Argatroban binds directly and reversibly to the active site of thrombin (factor IIa), blocking its ability to convert fibrinogen to fibrin and to activate platelets. This inhibition interrupts the final step of the coagulation cascade, producing rapid anticoagulation without affecting upstream clotting factors.

Argatroban may be associated with several adverse reactions, which are categorized by frequency and clinical severity.

Common Side Effects

• Bleeding at catheter sites: mild to moderate hemorrhage.
• Thrombocytopenia: reduction in platelet count.
• Elevated liver enzymes: mild transaminase increase.
• Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects

• Major hemorrhage: life‑threatening bleeding.
• Anaphylaxis: severe allergic reaction.
• Hepatic failure: significant liver dysfunction.

When using Novastan, clinicians should consider specific safety measures.

• Renal impairment: monitor coagulation parameters closely.
• Hepatic dysfunction: dose adjustment may be required.
• Concomitant anticoagulants: increase risk of bleeding; avoid unless clinically justified.
• Recent surgery or trauma: assess bleeding risk before initiating therapy.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Argatroban can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk.
• Potent CYP2C9 inhibitors (e.g., fluconazole, voriconazole): may raise argatroban plasma levels.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (e.g., clopidogrel, aspirin): additive antithrombotic effect, monitor for bleeding.
• NSAIDs (e.g., ibuprofen, naproxen): increase risk of gastrointestinal bleeding.
• High‑dose steroids: may affect coagulation parameters, observe closely.